For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
As of close of business last night, Regeneron Pharmaceuticals, Inc’s stock clocked out at $563.8, down -2.44% from its previous closing price of $577.9. In other words, the price has decreased by -$2.44 from its previous closing price. On the day, 1.12 million shares were traded. REGN stock price reached its highest trading level at $588.6999 during the session, while it also had its lowest trading level at $562.785.
Ratios:
To gain a deeper understanding of REGN’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 7.98 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 15.51. For the most recent quarter (mrq), Quick Ratio is recorded 3.72 and its Current Ratio is at 4.60. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.09.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Rothschild & Co Redburn on August 14, 2025, initiated with a Buy rating and assigned the stock a target price of $890.
Wells Fargo Downgraded its Overweight to Equal Weight on May 30, 2025, while the target price for the stock was maintained at $580.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Nov 01 ’24 when McCourt Marion sold 1,000 shares for $844.61 per share. The transaction valued at 844,610 led to the insider holds 12,931 shares of the business.
MARION E MCCOURT bought 1,000 shares of REGN for $844,610 on Nov 01 ’24. On Oct 01 ’24, another insider, RYAN ARTHUR F, who serves as the Director of the company, sold 100 shares for $1048.78 each. As a result, the insider received 104,878 and left with 17,582 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, REGN now has a Market Capitalization of 59755470848 and an Enterprise Value of 53694480384. As of this moment, Regeneron’s Price-to-Earnings (P/E) ratio for their current fiscal year is 14.21, and their Forward P/E ratio for the next fiscal year is 14.01. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 10.84. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.20 while its Price-to-Book (P/B) ratio in mrq is 2.00. Its current Enterprise Value per Revenue stands at 3.778 whereas that against EBITDA is 12.021.
Stock Price History:
The Beta on a monthly basis for REGN is 0.32, which has changed by -0.50997776 over the last 52 weeks, in comparison to a change of 0.1716845 over the same period for the S&P500. Over the past 52 weeks, REGN has reached a high of $1192.54, while it has fallen to a 52-week low of $476.49. The 50-Day Moving Average of the stock is 0.86%, while the 200-Day Moving Average is calculated to be -10.35%.
Shares Statistics:
It appears that REGN traded 1.06M shares on average per day over the past three months and 1015690 shares per day over the past ten days. A total of 104.60M shares are outstanding, with a floating share count of 102.13M. Insiders hold about 3.64% of the company’s shares, while institutions hold 86.30% stake in the company. Shares short for REGN as of 1755216000 were 2349138 with a Short Ratio of 2.21, compared to 1752537600 on 2074491. Therefore, it implies a Short% of Shares Outstanding of 2349138 and a Short% of Float of 2.34.
Earnings Estimates
The current assessment of Regeneron Pharmaceuticals, Inc (REGN) involves the perspectives of 19.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is $9.08, with high estimates of $11.38 and low estimates of $6.65.
Analysts are recommending an EPS of between $43.33 and $35.0 for the fiscal current year, implying an average EPS of $39.37. EPS for the following year is $35.98, with 11.0 analysts recommending between $46.12 and $26.77.
Revenue Estimates
In the current quarter, 19 analysts expect revenue to total $3.57B. It ranges from a high estimate of $3.8B to a low estimate of $3.39B. As of the current estimate, Regeneron Pharmaceuticals, Inc’s year-ago sales were $3.72BFor the next quarter, 19 analysts are estimating revenue of $3.61B. There is a high estimate of $4.05B for the next quarter, whereas the lowest estimate is $3.37B.
A total of 24 analysts have provided revenue estimates for REGN’s current fiscal year. The highest revenue estimate was $14.55B, while the lowest revenue estimate was $13.57B, resulting in an average revenue estimate of $13.89B. In the same quarter a year ago, actual revenue was $14.2BBased on 24 analysts’ estimates, the company’s revenue will be $14.52B in the next fiscal year. The high estimate is $15.54B and the low estimate is $13.03B.
